Claims for Patent: 8,758,733

Summary for Patent: 8,758,733

Title:	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Abstract:	The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Inventor(s):	Ahluwalia; Gurpreet (Orange, CA), Beddingfield; Frederick C. (Pacific Palisades, CA), Edwards; Sydney G. (Aliso Viejo, CA), Whitcup; Scott M. (Laguna Hills, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/738,732
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,758,733
Patent Claims:	1. A method of growing eyelashes in chemotherapy patients, the method comprising applying 0.03% w/v bimatoprost to the eyelids of one selected from the group consisting of before, during, or after chemotherapeutic treatment. 2. The method of claim 1, wherein the 0.03% w/v bimatoprost is applied at least once a day after chemotherapeutic treatment. 3. The method of claim 2, wherein the method results in eyelashes which are longer or thicker or darker in comparison to the eyelashes of chemotherapy patients who did not receive 0.03% bimatoprost. 4. The method of claim 2, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment. 5. The method of claim 4, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment. 6. The method of claim 2, wherein the number or length of eyelashes increase in comparison to post-chemotherapeutic patients who did not receive 0.03% w/v bimatoprost. 7. The method of claim 1, wherein the bimatoprost is added during and after chemotherapeutic treatment. 8. The method of claim 2, wherein the method is applied twice a day. 9. The method of claim 8, wherein the bimatoprost is applied to the upper or lower eyelid margin of each eye. 10. The method of claim 2, wherein the method effectively treats post-chemotherapeutic hypotrichosis. 11. The method of claim 1, further comprising the step of administering one selected from the group consisting of Minoxidil.RTM. and Propecia.RTM.. 12. The method of claim 1, wherein the method results in lower incidence of conjunctival hyperemia, punctate keratitis, erythema of the eyelid, eye pruritus and skin hyperpigmentation than in patients receiving 0.03% w/v bimatoprost for treatment of idiopathic hypotrichosis. 13. A method of treating loss of eyelashes in patients undergoing chemotherapy, the method comprising applying 0.03% w/v bimatoprost to the eyelids of one selected from the group consisting of before, during, and after chemotherapeutic treatment. 14. The method of claim 13, wherein the 0.03% bimatoprost is applied at least once a day. 15. The method of claim 14, wherein the method results in eyelashes which are longer or thicker or darker in comparison to the eyelashes of patients who did not receive 0.03% bimatoprost. 16. The method of claim 14, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment. 17. The method of claim 14, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment. 18. The method of claim 14 wherein the 0.03% w/v bimatoprost is applied once a day. 19. The method of claim 18 wherein the 0.03% w/v bimatoprost is applied to the upper eyelid. 20. The method of claim 18 wherein the 0.03% w/v bimatoprost is applied to the upper eyelid or the lower eyelid.